23.01.2020 – Polyphor AG

Polyphor appoints Gökhan Batur as Chief Executive Officer

Polyphor AG / Key word(s): Personnel
Polyphor appoints Gökhan Batur as Chief Executive Officer

23-Jan-2020 / 18:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.


Allschwil, Switzerland, January 23, 2020

Polyphor appoints Gökhan Batur as Chief Executive Officer

Polyphor AG (SIX: POLN) announced today that Gökhan Batur, currently Chief
Commercial Officer (CCO) of Polyphor has been appointed as Chief Executive
Officer (CEO) effective immediately. He will succeed Giacomo DiNepi, who
will retire after a long-standing and successful career in the
Pharmaceutical industry.

Kuno Sommer, Chairman of the Board of Directors of Polyphor, said: "I am
very pleased that with Gökhan we are appointing a new CEO of Polyphor with a
broad and international experience in the healthcare industry and an
in-depth understanding of Polyphor and our business. Gökhan has joined
Polyphor in 2019 with a strong track record in leadership, strategy and
execution. Having the opportunity to work with him as a member of the
executive committee, we are convinced that he is the right person to lead
Polyphor. I would also like to thank Giacomo for his leadership, dedication
and great work over the last years, most notably the successful IPO of
Polyphor in 2018. I wish him all the best for the future."

Gökhan Batur has more than 15 years of healthcare industry experience.
Before joining Polyphor, he assumed various management roles at MSD, most
recently serving as Executive Director, Global Brand Leader, Antibiotics,
responsible for leading the entire Merck antibiotics portfolio managing
multiple in-line, launch and pipeline products and sales of ~2 billion
dollars. He received his BS in Management Information Systems from Bosphorus
University, Istanbul.

The Board and Management Team of Polyphor will provide a business update,
followed by a Q&A session on February 20, 2020 at 14.00 CET.

For further information please contact:

For Investors:
Hernan Levett
Chief Financial Officer
Polyphor Ltd.
Tel: +41 61 567 16 24
Email: IR@polyphor.com

For Media:
Stephan Feldhaus
Feldhaus & Partner GmbH
Tel: +41 79 865 92 56
Email: feldhaus@feldhaus-partner.ch

About Polyphor
Polyphor is a clinical stage, Swiss biopharmaceutical company focused on the
discovery and de-velopment of immuno-oncology compounds and a new class of
antibiotics. Polyphor is advancing balixafortide (POL6326) in a Phase III
trial in combination with eribulin in patients with advanced breast cancer,
and exploring its potential in other cancer indications. In addition, it has
discovered and is developing the Outer Membrane Protein Targeting
Antibiotics (OMPTA). OMPTA are po-tentially the first new class of
antibiotics in clinical development in the last 50 years against
Gram-negative bacteria. The company's lead OMPTA program is an inhaled
formulation of murepavadin for the treatment of Pseudomonas aeruginosa
infections in patients with cystic fibrosis. Polyphor is based in Allschwil
near Basel and is listed on the SIX Swiss Exchange (SIX: POLN). For more
information, please visit www.polyphor.com.

This press release contains forward-looking statements which are based on
current assumptions and forecasts of the Polyphor management. Known and
unknown risks, uncertainties, and other factors could lead to material
differences between the forward-looking statements made here and the actual
development, in particular Polyphor's results, financial situation, and
performance. Readers are cautioned not to put undue reliance on
forward-looking statements, which speak only of the date of this
communication. Polyphor disclaims any intention or obligation to update and
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.


End of ad hoc announcement